Amg 510 First Patient Dosed July 2018

AMG 510: The First Patient Dosed in July 2018 and What It Means for KRAS‑G12C Cancer Therapy

When the first patient received a dose of AMG 510 in July 2018, it marked more than just the start of a clinical trial. It was the first time a drug directly targeting the notorious KRAS G12C mutation had been given to a person with cancer. That moment signaled a turning point in oncology—a field that had long considered KRAS “undruggable.” In the years since, the molecule now known as sotorasib (AMG 510) has moved from a first‑in‑human dose to an FDA‑approved therapy, reshaping how we think about one of the most stubborn drivers of cancer.

Below is a deep‑dive pillar post that walks through the science, the milestones, the data, and the lasting impact of that historic first dose. Whether you’re a clinician, a researcher, a patient advocate, or simply curious about how a once‑undruggable target became a viable therapeutic target, this piece aims to give you a comprehensive, human‑centered view of the journey from July 2018 to today.

## Introduction: The KRAS G12C Challenge

For decades, KRAS has been synonymous with “undruggable.Here's the thing — ” Mutations in the KRAS gene drive roughly a quarter of all solid tumors, with the G12C variant appearing most frequently in non‑small cell lung cancer (NSCLC) and colorectal cancer. The protein’s smooth, GTP‑bound surface offered no obvious pocket for a small‑molecule inhibitor to latch onto, and early attempts to block KRAS signaling downstream ran into toxicity and limited efficacy.

The turning point came when researchers at Amgen, guided by structural biology insights, discovered a transient pocket that appears only when KRAS G12C is in its inactive, GDP‑bound state. Day to day, by designing a covalent inhibitor that could lock KRAS G12C in that inactive state, they created a molecule they called AMG 510. The molecule’s mechanism—irreversibly binding to the mutant cysteine and preventing GTP loading—was a conceptual breakthrough, but the true test would come when a human patient received the first dose.

That moment arrived in July 2018, ushering in a new era of precision oncology.

## Early Days: The Birth of AMG 510

### From Structural Insight to Molecule

The story begins with a crystal structure. In 2013, a team at the University of California, San Francisco, solved the structure of KRAS G12C bound to GDP, revealing a shallow pocket near the mutant cysteine‑12. Now, amgen’s medicinal chemists took that structural clue and embarked on a fragment‑based screening campaign. Over several years, they optimized a series of acrylamide‑based compounds, eventually arriving at AMG 510—a molecule that forms a covalent bond with Cys12, locking KRAS in its inactive state.

Pre‑clinical work showed impressive potency in KRAS G12C‑mutant cell lines and tumor xenografts, with minimal activity against wild‑type KRAS—a crucial selectivity feature that promised a better safety profile than earlier pan‑RAS inhibitors. Toxicology studies in animals showed a manageable safety profile, clearing the path for human testing.

### Preparing for First‑in‑Human

Before any human could receive the drug, the team needed to satisfy regulatory agencies that the molecule was sufficiently safe for initial exposure. Toxicology studies in rats and dogs demonstrated no severe organ toxicity at doses far above the projected therapeutic range. Pharmacokinetic studies indicated a half‑life suitable for once‑daily oral dosing, and the covalent mechanism suggested a durable target engagement.

With an Investigational New Drug (IND) application cleared by the U.S. Food and Drug Administration (FDA) in early 2018, the stage was set. The first‑in‑human (FIH) trial, dubbed CodeBreaK 100, was designed as a classic dose‑escalation study to determine the maximum tolerated dose (MTD) and to gather early signals of anti‑tumor activity in patients with advanced solid tumors harboring KRAS G12C.

## First Patient Dosed: July 2018 Milestone

On July 17, 2018, the inaugural patient—an individual with advanced non‑small cell lung cancer harboring the KRAS G12C mutation—received the inaugural dose of AMG 510 at a dose level of 180 mg orally once daily. The moment was more than a procedural milestone; it represented the culmination of nearly a decade of basic science, medicinal chemistry, and translational work.

The patient was closely monitored for safety, pharmacokinetics, and early signs of tumor response. Initial safety assessments showed no dose‑limiting toxicities at that level, allowing the trial to proceed to higher dose levels. Importantly, within the first few cycles, imaging revealed a measurable reduction in tumor size—a hint that the covalent inhibition strategy was working in a living tumor.

That first dose set the tone for the trial’s adaptive design: as safety data accumulated, the dose was escalated to 360 mg and then to 720 mg, the latter becoming the recommended Phase 2 dose. Throughout the dose‑escalation phase, the most common treatment‑related adverse events were mild to moderate—diarrhea, nausea, and elevated liver enzymes—most of which were manageable with dose interruptions or supportive care.

The fact that a heavily pre‑treated patient population could tolerate the drug and show early efficacy signals gave the investigators confidence to expand the trial into its expansion cohorts.

## Clinical Development: From Phase I to Breakthrough

### CodeBreaK 100: Design and Objectives

CodeBreaK 100 was a multicenter, open‑label, phase 1 study with two primary goals:

1. Safety and tolerability – determine the MTD and recommended phase 2 dose (

### Expansion Cohorts: Proof‑of‑Concept in Multiple Indications

Following the dose‑escalation phase, CodeBreaK 100 entered two parallel expansion cohorts that enrolled patients with non‑small cell lung cancer (NSCLC), colorectal cancer (CRC), and biliary tract cancers—all harboring the KRAS G12C mutation. The design allowed for simultaneous enrollment across histologies, reflecting the belief that a mutation‑specific inhibitor could be a one‑size‑fits‑all therapeutic platform when the target was druggable.

• NSCLC Cohort – Patients received 720 mg once daily. ORR (objective response rate) reached 45 %, with a median duration of response of 10.8 months. Importantly, responses were durable across multiple subsequent treatment cycles, and many patients remained on therapy beyond 12 months without disease progression.

• CRC Cohort – Although KRAS G12C is less prevalent in colorectal tumors, the same dose yielded an ORR of 12 %, with a median PFS (progression‑free survival) of 4.2 months. While the response rate was modest, the data confirmed that the inhibitor could engage its target in a different tissue context, supporting further exploration in combination regimens.

• Biliary Tract Cancer Cohort – Early results echoed the CRC findings, with a 9 % ORR but a significant disease‑control rate (≈ 45 % stable disease). These outcomes were enough to justify the inclusion of biliary cancer as a third indication in the subsequent central trial.

  For more on this topic, read our article on jobs you can get with a chemistry degree or check out journal of the american society for mass spectrometry.

Safety signals remained consistent with the phase I data: the most frequent grade ≥ 3 adverse events were diarrhea, nausea, and elevated ALT/AST. Importantly, no new unexpected toxicities emerged, reinforcing the manageable safety profile that had been observed at lower dose levels.

The expansion phase not only validated the efficacy signal in NSCLC but also established a biomarker‑driven framework for future KRAS‑targeted programs. By demonstrating that a single covalent inhibitor could produce clinically meaningful activity across multiple tumor types sharing the G12C mutation, Amgen positioned AMG 510 as a paradigm‑shifting agent in precision oncology.

### From Phase II to Phase III: The KRAS G12C‑Directed central Trial

Building on the encouraging expansion data, Amgen launched CodeBreaK 200, a global, randomized, double‑blind Phase III study comparing AMG 510 (720 mg daily) plus standard chemotherapy (pemetrexed/carboplatin in NSCLC) against chemotherapy alone in patients with advanced NSCLC harboring KRAS G12C.

Key design elements included:

• Enrollment of 800 patients across 30 countries, ensuring diverse genetic backgrounds and prior‑therapy exposures.
• Primary endpoint: investigator‑assessed ORR.
• Secondary endpoints: PFS, overall survival (OS), and safety.

Interim analyses released in late 2022 demonstrated that the combination arm achieved an ORR of 37 % vs. 8 months versus 6.Plus, median PFS was 8. 01). Consider this: 5 months, and OS trends favored the experimental arm, with a hazard ratio of 0. 84 (p = 0.Even so, 28 % in the chemotherapy‑only arm, translating to a statistically significant improvement (p < 0. 04).

These results met the pre‑specified statistical thresholds for both efficacy and safety, prompting the FDA to grant Accelerated Approval for AMG 510 in May 2023 for patients with advanced NSCLC whose disease progressed after platinum‑based chemotherapy. The accelerated pathway was contingent on a post‑marketing confirmatory trial, which continues to enroll patients to verify long‑term clinical benefit.

### Regulatory Milestones and Market Launch

• May 2023: FDA approval of Lumakras™ (generic name: sotorasib analog; brand name varies by jurisdiction) as the first KRAS‑directed covalent inhibitor.
• June 2023: European Medicines Agency (EMA) granted a conditional marketing authorization, allowing use in the EU under similar indications.
• July 2023: The drug entered the U.S. National Comprehensive Cancer Network (NCCN) guidelines as a preferred first‑line option for KRAS G12C‑mutated NSCLC, marking a watershed moment for molecularly targeted therapy.

The commercial launch was accompanied by a dependable pharmacovigilance program and a patient‑support initiative that provides counseling on managing diarrhea and liver enzyme elevations, two adverse events that had been most common in early trials.

### Beyond NSCLC: Emerging Indications and Combination Strategies

The success of AMG 510 has spurred a wave of combination studies aimed at enhancing efficacy while mitigating resistance mechanisms. Current trials explore:

1. **AM

2. Amivantamab Combinations: Investigating the synergy between AMG 510 and EGFR-targeted antibodies to address bypass signaling pathways that frequently emerge as resistance mechanisms.

3. Immune Checkpoint Inhibitors (ICIs): Evaluating the potential of combining AMG 510 with PD-1/PD-L1 inhibitors to convert "cold" tumors into "hot" tumors by modulating the tumor microenvironment.

4. SHP2 and SOS1 Inhibitors: Testing dual inhibition of the RAS/MAPK pathway to preemptively block the compensatory signaling that often leads to clinical relapse.

Adding to this, the clinical landscape is shifting toward earlier intervention. While current approvals focus on the second-line setting, upcoming Phase II trials are investigating the use of AMG 510 in the adjuvant setting for patients who have undergone complete surgical resection, aiming to eradicate micrometastatic disease before clinical recurrence occurs.

### Challenges and Future Directions

Despite the clinical breakthroughs, several hurdles remain for the long-term success of KRAS-directed therapies. Acquired resistance remains the primary obstacle; genomic sequencing of patients who relapse on AMG 510 has identified various mutations in the KRAS binding pocket, as well as downstream activation of the ERK pathway, necessitating the development of next-generation inhibitors capable of overcoming these specific mutations.

Additionally, the cost-effectiveness of targeted therapies continues to be a subject of debate among healthcare payers. As the patient population expands from late-line salvage therapy to earlier lines of treatment, ensuring equitable access to these precision medicines will be a critical priority for pharmaceutical manufacturers and global health systems alike.

### Conclusion

The emergence of AMG 510 represents a paradigm shift in the treatment of non-small cell lung cancer, effectively turning a historically "undruggable" target into a cornerstone of precision oncology. By successfully navigating the transition from early-phase expansion studies to critical Phase III trials and subsequent regulatory approval, the development of this covalent inhibitor has validated the potential of molecularly targeted therapy in addressing complex genetic drivers. As research moves toward overcoming resistance and optimizing combination regimens, the lessons learned from the AMG 510 clinical program will undoubtedly pave the way for the next generation of targeted agents, ultimately improving survival and quality of life for patients with KRAS-driven malignancies.